TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Disorders A - Z  »  NINDS Clinical Trials  » 

Skip secondary menu

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)

See All Stroke Trials

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, is looking for individuals to participate in clinical studies. Participating in clinical trials allows you to play an active role in research on the nature and causes of many disorders of the brain and nervous system, and to possibly help physician-scientists develop future treatments. The information below is designed to help you quickly learn about actively recruiting research studies for which you or someone you know may be eligible.


A transient ischemic attack (TIA) is a brief episode of neurological dysfunction that often is a harbinger of disabling strokes.  An ischemic stroke is a cerebral infarction or brain attack.  The primary goal of the POINT trial is to determine if the drug clopidogrel (used to reduce or prevent blood clots) combined with aspirin is effective in preventing ischemic stroke and myocardial infarction (heart attack).

In this 7-year trial, which will recruit 5,840 subjects, participants will be randomized to receive either the study drug clopidogrel combined with aspirin or a placebo combined with aspirin. Individuals over age 18 who can be randomized and begin treatment within 12 hours of the time last known free of new ischemic symptoms will be enrolled. Participants will be followed for 90 days after randomization.

If trial results are positive, treatment with clopidogrel could reduce the burden of stroke in the U.S. and substantially reduce costs of care.


Phase 3


Eligibility Criteria:

Please follow this link for trial eligibility information to share with your doctor.

Study Design: 

Interventional, Purpose: Treatment


Study Locations: 

Multiple locations worldwide


For more information:

Contact: Mary Farrant, MBA BSN RN; Tel: 415-502-7304; Email:

Last Reviewed August 4, 2016